Aurinia (AUPH) | Financial Analysis & Statements
Aurinia Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
77.1M
Gross Profit
68.3M
88.59%
Operating Income
33.2M
43.10%
Net Income
210.8M
273.35%
EPS (Diluted)
$1.53
Balance Sheet Metrics
Total Assets
751.6M
Total Liabilities
170.3M
Shareholders Equity
581.3M
Debt to Equity
0.29
Cash Flow Metrics
Operating Cash Flow
206.1M
Free Cash Flow
45.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Aurinia Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 283.1M | 235.1M | 175.5M | 134.0M | 45.6M |
| Cost of Goods Sold | 32.7M | 28.2M | 14.1M | 5.7M | 1.1M |
| Gross Profit | 250.4M | 206.9M | 161.4M | 128.4M | 44.5M |
| Gross Margin % | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% |
| Operating Expenses | |||||
| Research & Development | 32.5M | 20.8M | 49.6M | 45.0M | 51.1M |
| Selling, General & Administrative | 101.8M | 172.0M | 195.0M | 196.4M | 173.5M |
| Other Operating Expenses | 9.5M | -4.3M | 8.4M | -1.5M | 574.0K |
| Total Operating Expenses | 143.8M | 188.5M | 253.1M | 239.8M | 225.2M |
| Operating Income | 106.6M | 18.4M | -91.7M | -111.5M | -180.7M |
| Operating Margin % | 37.6% | 7.8% | -52.2% | -83.2% | -396.3% |
| Non-Operating Items | |||||
| Interest Income | 13.6M | 17.0M | 17.0M | 5.1M | 529.0K |
| Interest Expense | 4.3M | 4.8M | 2.8M | 0 | 0 |
| Other Non-Operating Income | -1.6M | -23.1M | - | - | - |
| Pre-tax Income | 114.2M | 7.4M | -77.5M | -106.4M | -180.2M |
| Income Tax | -173.0M | 1.7M | 551.0K | 1.8M | 760.0K |
| Effective Tax Rate % | -151.6% | 22.8% | 0.0% | 0.0% | 0.0% |
| Net Income | 287.2M | 5.8M | -78.0M | -108.2M | -181.0M |
| Net Margin % | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% |
| Key Metrics | |||||
| EBITDA | 139.6M | 54.8M | -63.0M | -103.6M | -177.4M |
| EPS (Basic) | $2.14 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
| EPS (Diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
| Basic Shares Outstanding | 134367000 | 143057000 | 143236000 | 141915000 | 129369000 |
| Diluted Shares Outstanding | 134367000 | 143057000 | 143236000 | 141915000 | 129369000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Aurinia Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 80.2M | 83.4M | 48.9M | 94.2M | 231.9M |
| Short-term Investments | 317.8M | 275.0M | 301.6M | 295.2M | 234.2M |
| Accounts Receivable | 41.5M | 36.5M | 24.1M | 13.5M | 15.4M |
| Inventory | 45.7M | 39.2M | 39.7M | 24.8M | 19.3M |
| Other Current Assets | 1.1M | 1.1M | 1.0M | 1.3M | 796.0K |
| Total Current Assets | 492.0M | 446.6M | 424.8M | 442.5M | 513.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 77.5M | 96.1M | 113.2M | 4.9M | 5.4M |
| Goodwill | 3.8M | 4.4M | 5.0M | 6.4M | 8.4M |
| Intangible Assets | 3.8M | 4.4M | 5.0M | 6.4M | 8.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 176.3M | 823.0K | 1.5M | 13.3M | 11.8M |
| Total Non-Current Assets | 259.6M | 104.0M | 123.3M | 28.3M | 30.0M |
| Total Assets | 751.6M | 550.6M | 548.1M | 470.9M | 543.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.3M | 5.2M | 4.3M | 3.1M | 3.9M |
| Short-term Debt | 17.6M | 15.1M | 15.6M | 936.0K | 1.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 2.5M | 1.5M | 2.4M | 2.0M | 4.4M |
| Total Current Liabilities | 93.7M | 97.8M | 77.2M | 46.1M | 40.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 57.2M | 64.3M | 82.0M | 7.2M | 7.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 6.7M | 11.1M | 10.9M | 12.2M | - |
| Total Non-Current Liabilities | 76.5M | 75.4M | 92.9M | 19.3M | 23.6M |
| Total Liabilities | 170.3M | 173.2M | 170.1M | 65.4M | 64.3M |
| Equity | |||||
| Common Stock | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B |
| Retained Earnings | -649.4M | -936.6M | -942.3M | -864.3M | -756.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 581.3M | 377.5M | 378.0M | 405.4M | 479.1M |
| Key Metrics | |||||
| Total Debt | 74.8M | 79.4M | 97.6M | 8.1M | 8.7M |
| Working Capital | 398.2M | 348.8M | 347.6M | 396.4M | 472.7M |
Balance Sheet Composition
Aurinia Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 287.2M | 5.8M | -78.0M | -108.2M | -181.0M |
| Depreciation & Amortization | 19.4M | 19.4M | 11.6M | 2.7M | 2.8M |
| Stock-Based Compensation | 14.7M | 31.6M | 45.3M | 32.3M | 31.2M |
| Working Capital Changes | -9.6M | -6.0M | -10.0M | -4.4M | -16.3M |
| Operating Cash Flow | 135.3M | 51.5M | -32.6M | -79.2M | -153.3M |
| Investing Activities | |||||
| Capital Expenditures | -252.0K | -281.0K | -718.0K | -292.0K | -303.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -526.6M | -545.8M | -523.5M | -524.0M | -439.0M |
| Investment Sales | 494.1M | 585.4M | 529.4M | 464.3M | 354.4M |
| Investing Cash Flow | -32.8M | 39.3M | -6.7M | -60.6M | -102.7M |
| Financing Activities | |||||
| Share Repurchases | -98.2M | -40.2M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -13.1M | -12.0M | -10.0M | 0 | 0 |
| Financing Cash Flow | -121.1M | -58.4M | -10.0M | 0 | 196.7M |
| Free Cash Flow | 135.4M | 44.1M | -34.2M | -79.8M | -159.2M |
| Net Change in Cash | -18.5M | 32.4M | -49.3M | -139.8M | -59.2M |
Cash Flow Trend
Aurinia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.80
Forward P/E
19.68
Price to Book
3.67
Price to Sales
7.41
PEG Ratio
0.00
Profitability Ratios
Profit Margin
101.47%
Operating Margin
55.68%
Return on Equity
59.91%
Return on Assets
11.16%
Financial Health
Current Ratio
5.25
Debt to Equity
12.87
Beta
1.52
Per Share Data
EPS (TTM)
$2.07
Book Value per Share
$4.39
Revenue per Share
$2.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AUPH | 2.1B | 7.80 | 3.67 | 59.91% | 101.47% | 12.87 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






